Evidence-based SGLT2 inhibitor and GLP-1 receptor agonist use by race in the VA healthcare system

Importance: Adoption of novel therapeutics often lags for Black versus non-Hispanic White patients. Seminal clinical trials established the cardiovascular efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in patients with type 2 di...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Demetria M. Bolden, Vanessa Richardson, Taufiq Salahuddin, Kamal Henderson, Paul L. Hess, Sridharan Raghavan, David R. Saxon, P. Michael Ho, Stephen W. Waldo, Gregory G. Schwartz
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2025-06-01
Edice:	American Journal of Preventive Cardiology
Témata:	Type 2 diabetes SGLT2i GLP-1RA Atherosclerotic cardiovascular disease Pharmacoequity Health disparity
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2666667725000388
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!